Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD).

ABSTRACT:

Introduction

Sodium-glucose cotransporter-2 inhibitors have demonstrated cardiorenal protective effects in adults with chronic kidney disease (CKD), but their efficacy and safety in paediatric CKD remain uncertain. Treatment for hereditary kidney disease in children is limited. This DAPA-PedHKD study aims to evaluate the effectiveness and safety of combining renin-angiotensin-aldosterone system inhibitors (RAASi) with dapagliflozin compare to RAASi alone in children with hereditary kidney disease accompanied by proteinuria.

Methods and analysis

DAPA-PedHKD is a multicentre, randomised, crossover, open-label clinical trial. Patients aged 6-18 years with hereditary kidney disease will be eligible. All patients must have received stable RAASi therapy for at least 4 weeks, with

SUBMITTER: Zhang W 

PROVIDER: S-EPMC12706236 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature